Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 17/20 | 1.00 |
| ▸ | PPARA | Q07869 | 17/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL979058 | 0.89 | PPARG (1.00) | PPARGPPARAALDH1A1GAASIRT2 | |
| SCHEMBL978747 | 0.81 | PPARG (1.00) | PPARGPPARAALDH1A1 | |
| SCHEMBL977475 | 0.81 | PPARG (1.00) | PPARGPPARAALDH1A1 | |
| SCHEMBL11864635 | 0.79 | PPARG (0.76) | PPARGPPARAALDH1A1GAA | |
| SCHEMBL979305 | 0.79 | PPARG (1.00) | PPARGPPARAALDH1A1SIRT2 | |
| SCHEMBL978870 | 0.78 | PPARG (0.64) | PPARGPPARAHDAC1HDAC8SIRT2 | |
| SCHEMBL980101 | 0.78 | PPARG (1.00) | PPARGPPARA | |
| SCHEMBL5312651 | 0.75 | PPARG (0.61) | PPARGPPARAALDH1A1GAA | |
| SCHEMBL978588 | 0.74 | PPARG (1.00) | PPARGPPARAALDH1A1GAA | |
| SCHEMBL38663410 | 0.72 | PPARG (0.57) | PPARGPPARAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181181-B2 | 2-substituted-3-phenylpropionic acid derivatives and their use in the treatment of inflammatory bowel disease | ALBIREO AB (SE) | 2015-11-10 | — | — | US | claimed |
| US-20140303175-A1 | 2-Substituted-3-Phenylpropionic Acid Derivatives and Their Use in the Treatment of Inflammatory Bowel Disease | ALBIREO AB (SE) | 2014-10-09 | — | — | US | claimed |
| US-8785681-B2 | 2-substituted-3-phenylpropionic acid derivatives and their use in the treatment of inflammatory bowel disease | ALBIREO AB (SE) | 2014-07-22 | — | — | US | claimed |
| US-20110166157-A1 | 2-Substituted-3-Phenylpropionic Acid Derivatives and Their Use in the Treatment of Inflammatory Bowel Disease | ALBIREO AB (SE) | 2011-07-07 | — | — | US | claimed |
| US-20110021534-A1 | 2 -SUBSTITUTED- 3 -PHENYLPROPIONIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | ALBIREO AB (SE) | 2011-01-27 | — | — | US | claimed |
| EP-2125711-A1 | 2 -SUBSTITUTED- 3 -PHENYLPROPIONIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | Albireo Ab (SE) | 2009-12-02 | — | — | EP | claimed |
| WO-2008108735-A1 | 2 -SUBSTITUTED- 3 -PHENYLPROPIONIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | ALBIREO AB (SE) | 2008-09-12 | — | — | WO | claimed |
| US-9181181-B2 | 2-substituted-3-phenylpropionic acid derivatives and their use in the treatment of inflammatory bowel disease | ALBIREO AB (SE) | 2015-11-10 | — | — | US | disclosed |
| US-20140303175-A1 | 2-Substituted-3-Phenylpropionic Acid Derivatives and Their Use in the Treatment of Inflammatory Bowel Disease | ALBIREO AB (SE) | 2014-10-09 | — | — | US | disclosed |
| US-8785681-B2 | 2-substituted-3-phenylpropionic acid derivatives and their use in the treatment of inflammatory bowel disease | ALBIREO AB (SE) | 2014-07-22 | — | — | US | disclosed |
| US-20110166157-A1 | 2-Substituted-3-Phenylpropionic Acid Derivatives and Their Use in the Treatment of Inflammatory Bowel Disease | ALBIREO AB (SE) | 2011-07-07 | — | — | US | disclosed |
| US-20110021534-A1 | 2 -SUBSTITUTED- 3 -PHENYLPROPIONIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | ALBIREO AB (SE) | 2011-01-27 | — | — | US | disclosed |
| EP-2125711-A1 | 2 -SUBSTITUTED- 3 -PHENYLPROPIONIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | Albireo Ab (SE) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008108735-A1 | 2 -SUBSTITUTED- 3 -PHENYLPROPIONIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | ALBIREO AB (SE) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021534-A1 | 2 -SUBSTITUTED- 3 -PHENYLPROPIONIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | TPMT, FABP2, PTGES2 | PPARG 35/4885PPARA 25/4885HDAC1 2162/4885 |
| US-20140303175-A1 | 2-Substituted-3-Phenylpropionic Acid Derivatives and Their Use in the Treatment of Inflammatory Bowel Disease | TPMT, FABP2, PTGES3 | PPARG 25/4885PPARA 19/4885HDAC1 2138/4885 |
| US-20110166157-A1 | 2-Substituted-3-Phenylpropionic Acid Derivatives and Their Use in the Treatment of Inflammatory Bowel Disease | TPMT, FABP2, PTGES3 | PPARG 25/4885PPARA 19/4885HDAC1 2138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.